Cliantha Research is proud to announce the acquisition of Inflamax Research. Inflamax has locations in Toronto, ON; Neptune, NJ and Newark, NJ. Cliantha Research will have the capabilities to perform Phase I, II, III and IV clinical research in North America. Inflamax’s world renowned expertise in inflammatory disease research and patented natural allergen Environmental Exposure Chambers (EEC) shall allow Cliantha to conduct Asthma, Allergy, Ophthalmology, Tobacco research plus specialized pulmonary/respiratory therapeutic studies.
Cliantha Research is proud to announce the acquisition of Inflamax Research. Inflamax has locations in Toronto, ON; Neptune, NJ and Newark, NJ. Cliantha Research will have the capabilities to perform Phase I, II, III and IV clinical research in North America. Inflamax’s world renowned expertise in inflammatory disease research and patented natural allergen Environmental Exposure Chambers (EEC) shall allow Cliantha to conduct Asthma, Allergy, Ophthalmology, Tobacco research plus specialized pulmonary/respiratory therapeutic studies.
The two New Jersey clinics were acquired by Hill Top Research (St. Petersburg, FL), a wholly owned subsidiary of Cliantha Research since 2011. With two clinical sites in the U.S., Hill Top Research can conduct HRIPT studies as per FDA guidance.
“Inflamax is the leader in research in inflammatory disease with a specialty in Environmental Exposure Chamber technologies. Now we can provide our sponsors with advanced clinical trial designs along with a strong, highly experienced scientific team in North America. This acquisition brings us closer to our goal of offering highly specialized trials to our sponsor.” says Mr. Vijay Patel, Executive Director, Cliantha Research.
Dr. Piyush Patel, CEO of Inflamax Research, commented, “I am very excited about the future prospects of Inflamax Research and the Cliantha team working together. This merger brings together the best of our collective scientific research capabilities and expands our infrastructure and offerings to our clients. There are many synergies between Inflamax Research and Cliantha which will offer new and expanded opportunities to our clients.”
Both firms are committed to a smooth, well planned integration of services in North America and India. The synergy of the combined companies expands service offerings and will drive growth. The Inflamax Toronto Clinic and Chambers will continue to operate under the current leadership of Dr. Piyush Patel and Dr. Anne Marie Salapatek as Inflamax Research. The New Jersey Clinical units will be integrated with our US operation as Hill Top Research to offer world-class dermatology research studies such as HRIPT, Adhesion, Cumulative Irritation and PK studies.
About Inflamax Research
Dr. Piyush Patel is the founder of Inflamax Research and an internationally recognized allergy and asthma specialist. Inflamax is a full service CRO with a strong, highly experienced scientific team led by Dr. Anne Marie Salapatek that provides First-in-human, BA/BE, and Phase II, III, IV services. Inflamax maintains 100 beds in Toronto, ON and 100 beds in Neptune, NJ. Inflamax has expertise studying allergic rhino-conjunctivitis and asthma using both traditional field and controlled allergen challenge approaches. Inflamax utilizes direct allergen instillation models of Conjunctival Allergen Provocation Testing (CAPT), Nasal Allergen Challenge (NAC), Bronchial Allergen Challenge, as well as natural airborne allergen challenges via our validated EECs. Inflamax’s natural allergen Environmental Exposure Chambers (EEC) are state of the art facilities that tightly regulate temperature and humidity while simulating the level of allergen exposure patients would encounter in their everyday lives. By monitoring patients throughout the exposure, nasal, bronchial and ocular symptoms and signs may be evoked consistently and safely.
About Cliantha Research
Cliantha Research, is a global Contract Research Organization (CRO) providing integrated clinical offerings in Early Phase (Phase I/IIa), Late Phase (Phase II-IV), Bioequivalence (BA/BE), Clinical Endpoint Trials, Bioanalytical, Biosimilars, Dermatology, Biometrics and Personal Healthcare services. Our services have science at its foundation that is developed through regular and systematic training of the Cliantha Team. Cliantha offers Biosimilar, Biotech, Cosmetic, Generic, Personal Healthcare and Pharmaceutical companies a comprehensive range of clinical research and support services. Cliantha Research has acquired Hill Top Research, Karmic Lifesciences and Inflamax Research. The companies operate under their legacy brand name; however, we operate as one company – Cliantha. For more information please visit www.cliantha.in
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.